Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

Argenx jumps on Phase 3 data for blockbuster Vyvgart

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Monday 17 August →